Icon - Landmark medical trial finds drug ineffective

Landmark medical trial finds drug ineffective

A major clinical trial run by the Australasian Kidney Trials Network (AKTN) finds the drug allopurinol does not prevent worsening of kidney disease. The researchers have found allopurinol is ineffective in treating the condition, despite up to 20 per cent of kidney disease patients being prescribed the medication. 

The CKD-FIX two-year study, conducted with the AKTN, ran across 31 hospitals in Australia and New Zealand and involved 369 patients with stage 3 or 4 chronic kidney disease and at increased risk of kidney disease progression.

NZ lead investigator Dr Janak de Zoysa, Clinical Director of the Waitemata Renal Service, said the study would allow doctors to optimise clinical practice.

"Treatments that are proven not to be as effective as anticipated allow room for them to be stopped or not started in the first place, reducing unnecessary healthcare costs,” Dr de Zoysa said.

Download the Infographic explaining the trial here

Our newsCoronavirus (COVID-19)
Join our community to download